Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21202536 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL18714257 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17000183 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL14101720 | 0.80 | CYP3A4 (0.40) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16395570 | 0.79 | PIK3CD (0.36) | SMN1; SMN2CHRNB2CHRNA4CYP3A4CYP2D6 | |
| SCHEMBL29912172 | 0.79 | PIK3CD (0.39) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1090665 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL2120568 | 0.79 | PIK3CD (0.39) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7996117 | 0.78 | PIK3CD (0.35) | SMN1; SMN2CHRNB2CHRNA4CYP3A4CYP2D6 | |
| SCHEMBL4252351 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP3A4CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | SMN1; SMN2 2089/4885CHRNB2 4866/4885CHRNA4 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.